• info@icbcongress.com
• English
• Persian

• Login

Create Free Account

INTERNATIONAL CONGRESS OF

CancerGenetics

• LAT1 Amino Acid Transporter Overexpression and Tumor Growth in Glioblastoma: A Systematic Review

• Kimia Heydariyar,^1,* Hori Ghaneialvar,² Omid Raiesi,³ Alireza Vasiee,⁴
  1. Student Research Committee, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
  2. Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran
  3. Department of Parasitology, School of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran
  4. Department of Nursing, Faculty of Nursing and Midwifery, Ilam University of Medical Sciences, Ilam, Iran
  
  
  
• Introduction: The large neutral amino acid transporter 1 (LAT1, SLC7A5) mediates uptake of essential amino acids that fuel rapid proliferation in glioblastoma (GBM). Emerging evidence links LAT1 overexpression to accelerated tumor growth and poor patient outcomes, yet quantitative synthesis of these associations is lacking. We systematically reviewed preclinical and clinical studies to aggregate the impact of LAT1 overexpression on GBM progression and survival.
• Methods: We searched PubMed, EMBASE, Web of Science, and Scopus from inception through June 2025 using (“LAT1” OR “SLC7A5”) AND (“glioblastoma” OR “GBM”) AND (“tumor growth” OR “survival” OR “prognosis”). Eligible studies were in vivo xenograft experiments or human cohort studies reporting quantitative associations between LAT1 expression and tumor volume, proliferation indices, progression-free survival (PFS), or overall survival (OS). Two reviewers independently screened 1 092 records, extracted hazard ratios (HR), standardized mean differences (SMD), and odds ratios (OR), and assessed bias with SYRCLE’s tool for animal studies and the Newcastle–Ottawa Scale for clinical cohorts.
• Results: Across 10 clinical cohorts (n = 1 244 patients) and 6 xenograft studies (n = 168 mice), LAT1 overexpression was detected in 67.8% of GBM specimens (95% CI 64.2–71.3). High LAT1 expression conferred a pooled HR of 2.15 for OS (95% CI 1.85–2.50; p < 0.02) and 1.98 for PFS (95% CI 1.65–2.37; p < 0.01). In xenografts, LAT1-high tumors exhibited a 1.25 SMD increase in tumor volume versus controls (95% CI 1.02–1.48; p < 0.05) and a 52% higher Ki-67 index (95% CI 44–60%).
• Conclusion: Aggregated data demonstrate that LAT1 overexpression drives faster tumor growth in xenograft models and doubles the risk of progression and death in GBM patients. LAT1 represents both a prognostic biomarker and a promising therapeutic target to curb GBM aggressiveness.
• Keywords: LAT1; SLC7A5; glioblastoma; tumor growth